AMAG Pharma (AMAG) Reports Q1 Loss of $3.54/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharmaceuticals (AMAG) PT Lowered to $13 at Cowen
May 7, 2019 3:01 PM EDTCowen analyst Ken Cacciatore lowered the price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $13.00 (from $17.00) while maintaining a Market Perform rating.
The analyst commented, "AMAG is continuing to make aggressive investments in their current new product portfolio (Intrarosa & possibly Vyleesi later... More
